

limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, Research Education Program for Clinical Researchers and Clinicians.

*Date:* November 1, 2011.

*Time:* 11 a.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Gerald L. McLaughlin, PhD, Chief, Grants Review Branch and Contracts Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, B/START Review Committee.

*Date:* November 4, 2011.

*Time:* 8 a.m. to 8 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

*Contact Person:* Mark Swieter, PhD, Chief, Extramural Activities Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4235, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550, 301-435-1389, ms80x@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, HIV/AIDS Implementation Science Targeting Drug Using Populations: PEPFAR (R01).

*Date:* November 15, 2011.

*Time:* 9 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Garden Inn—Bethesda, 7301 Waverly Street, Bethesda, MD 20814.

*Contact Person:* Nadine Rogers, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892-9550, 301-402-2105, rogersn2@nida.nih.gov.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, Remote Monitoring System for Cocaine Ingestion.

*Date:* November 17, 2011.

*Time:* 10 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Gerald L. McLaughlin, PhD, Chief, Grants Review Branch and Contracts Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, DIDARP Review.

*Date:* December 13, 2011.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

*Contact Person:* Nadine Rogers, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892-9550, 301-402-2105, rogersn2@nida.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: October 17, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-27294 Filed 10-20-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: The Development of a Companion Diagnostic Kit for Predicting Therapeutic Efficacy of Anti-Cancer Agents

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent Application 61/144,501 entitled "Ratio Based Biomarker of Survival Utilizing PTEN and Phospho-AKT" [HHS Ref. E-025-2009/0-US-01], and all continuing applications and foreign counterparts, to 20/20 GeneSystems, Inc. The patent rights in this invention have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to:

the use of the Licensed Patent Rights limited to an FDA-approved (i) Laboratory Developed Test (LDT) offered as a service or (ii) in vitro diagnostic (IVD) kit distributed in commerce for human use of a protein panel predictive of the therapeutic effect of an anti-cancer agent in the treatment of kidney, lung, and breast cancers that includes at least one of the following proteins (phosphorylated or unphosphorylated): PTEN, Akt, mTOR.

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 21, 2011 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Patrick P. McCue, Ph.D., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-5560; Facsimile: (301) 402-0220; E-mail: mcccuepat@mail.nih.gov.

**SUPPLEMENTARY INFORMATION:** This invention concerns methods for the prognosis for a subject with cancer and to evaluate therapeutic regimens through the comparison of normalized expression values of two or more cancer-associated proteins. Several specific cancer-associated proteins are covered by this technology, including PTEN, phosphorylated Akt, phosphorylated mTOR, EGFR, phosphorylated MAPK, HER2, and HER3. Examined individually, these proteins do not provide discrimination of survival. However, examined together as protein ratios, the prognostic function survived multivariate analysis. The approach has been demonstrated for biliary tract, kidney, lung, and stomach cancers.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7 within thirty (30) days from the date of this published notice.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 13, 2011.

**Richard U. Rodriguez,**  
Director, Division of Technology Development  
& Transfer, Office of Technology Transfer,  
National Institutes of Health.

[FR Doc. 2011-27308 Filed 10-20-11; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Statement of Organization, Functions, and Delegations of Authority

Part M of the Substance Abuse and Mental Health Services Administration (SAMHSA) Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (DHHS) at 75, Number 157, pages 49942-49943, August 16, 2010, is amended to revise the functional statements for the Office of Policy, Planning, and Innovation (OPPI) and the Office of the Director (OD). These changes are necessary to strengthen the Office of Policy, Planning, and Innovation's cross-cutting policy role in the Agency as well as externally on a regional and national level. The changes are as follows:

*Section M.20, Functions* is amended as follows:

The functional statements for the Office of Policy, Planning and Innovation (MD) and the Office of the Director (MD1) are replaced with the following:

#### Office of Policy, Planning, and Innovation (MD)

The mission of the Office of Policy, Planning, and Innovation (OPPI) is to develop, coordinate, and communicate SAMHSA policy to improve behavioral health in America's communities.

The Office represents SAMHSA at meetings, both internal and external, while promoting SAMHSA's profile in health services research by collaborating with other Departments and Agencies. These include, but are not limited to other operational divisions within the U.S. Department of Health and Human Services (such as the National Institutes of Health, the Centers for Disease Control and Prevention, and the Centers for Medicare and Medicaid Services). The primary intent is to facilitate the adoption of data-driven policies and practices by those working in the field to improve behavioral health outcomes. While SAMHSA's primary mission is to serve those with behavioral health needs and foster health improvements, many partners and allies exist within

other fields that also play a crucial role in supporting and improving behavioral health. OPPI will seek to influence these partners and allies to encourage inclusion of behavioral health within their policy initiatives. These objectives are accomplished, in part, by the following OPPI functions and associated directives. OPPI:

1. Facilitates the exchange of information and coordinates activity between SAMHSA and State, Regional, Tribal, Federal, National, and International partners.

2. Works with SAMHSA's Office of the Administrator (OA), and SAMHSA's Offices and Centers to foster a unified understanding and operationalization of policy and budget directions for SAMHSA.

3. Partners with SAMHSA's Centers and Offices to achieve policy alignment in communications, evaluation, operations, and programs.

4. Provides policy advice to the Administrator.

5. Provides policy leadership in cross-cutting issue areas (*e.g.*, Disparities, Tribal Issues, Health Reform, Trauma & Justice, Women's Services, *etc.*).

6. Provides staff support, portfolio tracking, and coordination services for the Strategic Initiatives leaders and/or teams.

#### Office of the Director (MD1)

As the chief policy advisor to the Administrator, SAMHSA, the OPPI Director leads the review and development of policy in close coordination with the Administrator, SAMHSA Centers and Offices, DHHS and other Federal Agencies, Tribal, State and local governments, Congress and private constituents and groups.

The Office of the Director serves in other duties designed to promote the organizational mission. These are detailed below:

1. Provides leadership and coordination of strategic planning and provides an integrated and structured approach to program policy analysis, coordination, development, and communication.

2. Coordinates and collaborates with the Office of Financial Resources (OFR) to assure consistency and integration of Agency program policy in budget formulation, and coordinates and collaborates with Centers and programs to assure consistency and integration of Agency policy across programs.

3. Coordinates and collaborates with the OFR on appropriations presentations, analyses, implementation plans and reporting, and with Center and Office leadership on SAMHSA and program authority.

4. Manages and directs the staff and all programmatic activity in the Office of Policy, Planning and Innovation.

#### Delegation of Authority

All delegations and re-delegations of authority to officers and employees of SAMHSA which were in effect immediately prior to the effective date of this reorganization shall continue to be in effect pending further re-delegations, provided they are consistent with this reorganization.

These organizational changes are effective: October 21, 2011.

**Rose Shannon,**

Director, Division of Executive Correspondence.

[FR Doc. 2011-27235 Filed 10-20-11; 8:45 am]

BILLING CODE 4160-01-P

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-5484-N-32]

### Notice of Proposed Information Collection: Comment Request; Construction Complaint—Request for Financial Assistance

**AGENCY:** Office of the Assistant Secretary for Housing, HUD.

**ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

**DATES:** *Comments Due Date:* December 20, 2011.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Reports Liaison Officer, Department of Housing and Urban Development, 451 7th Street, SW., Washington, DC 20410, Room 9120 or the number for the Federal Information Relay Service (1-800-877-8339).

**FOR FURTHER INFORMATION CONTACT:** Karin Hill, Director, Office of Single Family Program Development, Department of Housing and Urban Development, 451 7th Street, SW., Washington, DC 20410, telephone (202) 708-2121 (this is not a toll free number) for copies of the proposed forms and other available information.

**SUPPLEMENTARY INFORMATION:** The Department is submitting the proposed